GRAIL, Inc.

About GRAIL, Inc.

GRAIL develops multi-cancer early-detection blood tests using high-intensity sequencing, population-scale clinical trials, and machine learning. Its Galleri test screens for over 50 cancers from a single blood draw, aiming to shift diagnosis from late-stage symptoms to early, treatable stages. The company conducts large prospective studies, partners with health systems, and pursues FDA approval to integrate screening into routine care. Founded in 2016 as a spin-out from Illumina, GRAIL operates laboratories in the United States and the United Kingdom and focuses on evidence generation, regulatory science, and equitable test access.